Author: Hannah Perry

Categories
Pharma Stocks

One Must-Buy High-Yield Healthcare Stock and One to Steer Clear Of

One Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and One to Avoid

The healthcare sector isn’t typically the go-to choice for income investors looking for high dividend yields. In fact, when ranked among the 11 sectors of the S&P 500, healthcare comes in eighth place based on average dividend yield. Nonetheless, there are still several healthcare stocks that offer attractive dividends, though not all of them are wise investments. Here, we explore one ultra-high-yield healthcare stock that is worth buying and another that should be avoided.

Buy Pfizer (NYSE: PFE)

While some may view Pfizer as a stock to avoid, primarily due to its recent struggles, those in search of income should consider it a solid investment. The pharmaceutical giant has seen its share price fall by over 50% since hitting a peak in late 2021. Despite a modest rebound this year, Pfizer’s stock performance lags noticeably behind the robust returns of the S&P 500.

The primary driver behind this underwhelming performance is the anticipated drop in sales from its COVID-19 vaccine, Comirnaty. After generating an impressive $37.8 billion in revenue in 2022, Pfizer expects that figure to decline to a mere $5 billion by 2024. Additionally, Pfizer is facing a significant patent cliff as several key medications will soon lose their exclusivity. Key drugs such as Inlyta (for kidney cancer) and Xeljanz (for autoimmune diseases) will lose their patents next year, with others, including Ibrance (breast cancer) and Eliquis (blood thinner), following in subsequent years.

Given these challenges, many income investors might feel hesitant about Pfizer’s appealing forward dividend yield of 5.66%. However, it is crucial to consider that Pfizer prioritizes maintaining and growing its dividend as part of its capital allocation strategy. More importantly, the company’s outlook may not be as bleak as it appears. Pfizer recently saw a return to year-over-year revenue growth for the first time since late 2022, and the management projects solid growth for the latter half of this decade, driven by promising new products and an expanding pipeline.

Among the recent initiatives, Pfizer’s experimental obesity treatment, danuglipron, shows promise. Moreover, the company is advancing several new oncology therapies into late-stage testing, including sigvotatug vedotin, atirmociclib, and mevrometostat. Given this strong pipeline and its attractive valuation at only 10.5 times forward earnings, Pfizer may be a compelling option for those focused on income generation.

Avoid Walgreens Boots Alliance (NASDAQ: WBA)

In contrast with Pfizer’s prospects, Walgreens Boots Alliance presents a much less optimistic picture. Although its forward dividend yield exceeds 9%, the underlying issues within the company pose significant risks for income investors. Walgreens’ stock has experienced a dramatic decline, plummeting nearly 80% from its three-year peak, with the company losing over half its market capitalization in 2024 alone.

While Pfizer’s financial figures improve, Walgreens is navigating troubled waters. The company’s adjusted earnings per share fell by a staggering 40.8% year-over-year in its latest quarter, and even lower earnings are expected in fiscal 2025. CEO Tim Wentworth revealed that around 2,000 of Walgreens’ more than 8,000 stores are not profitable, which raises serious concerns regarding its business model.

Walgreens is attempting to right the ship by closing approximately 1,200 unprofitable stores over the next three years while implementing cost-cutting measures. However, these efforts may not suffice to reassure income investors regarding the sustainability of its dividend. In a recent earnings call, Wentworth acknowledged that the company will “absolutely continue to monitor and make changes to our capital allocation,” which raises the alarm for potential dividend cuts in the future.

While aggressive investors seeking turnaround opportunities may find Walgreens an intriguing option, many prudent investors should consider standing aside for now. The risks associated with the company’s current financial health far outweigh any potential rewards.

Conclusion

In summary, income investors looking for solid dividends may find Pfizer to be an attractive option, thanks to its robust dividend policy and improving growth outlook, despite the challenges it faces related to patent expirations and declining vaccine sales. Conversely, Walgreens Boots Alliance, with its declining earnings and uncertain future, should be approached with caution, as the potential for dividend cuts loom large amidst declining profitability.

Categories
Small Stocks to Watch

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) Right for Your Investment Goals?

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

The Janus Henderson Small Cap Growth Alpha ETF (JSML) is designed to provide broad exposure to the Small Cap Growth segment of the US equity market. Launched on February 23, 2016, and sponsored by Janus Henderson, this passively managed exchange-traded fund has accumulated over $242.91 million in assets, making it a notable player among ETFs aimed at capitalizing on the small cap growth market.

Why Small Cap Growth?

Investing in small cap companies presents a compelling opportunity, primarily due to their potential for substantial growth. Companies with market capitalizations below $2 billion are typically in a position to achieve higher growth rates compared to their larger counterparts. However, this potential comes with increased risks. Growth stocks generally demonstrate higher sales and earnings growth rates but tend to be valued at higher multiples. This aspect means that while they may outperform value stocks in strong bull markets, value investments historically offer better returns across various market conditions.

Costs to Consider

When investing in ETFs, monitoring the expense ratio is crucial, as lower-cost products tend to yield better long-term results compared to their higher-cost counterparts, assuming other factors remain constant. The JSML has an annual operating expense ratio of 0.30%, which aligns with most peer products in this investment space. It also boasts a 12-month trailing dividend yield of 0.44%.

Sector Exposure and Top Holdings

Diversification is one of the key benefits of ETFs, which can help minimize single stock risk. However, it is essential for investors to review the actual holdings within the fund. The JSML ETF has a significant allocation to the Industrials sector, making up about 29.90% of the portfolio. Following this are the Healthcare and Information Technology sectors, which round out the top three. The top individual holding in the fund is Doximity Inc. Class A (DOCS), accounting for approximately 3.63% of total assets, followed by Corcept Therapeutics Incorporated (CORT) and Corvel Corporation (CRVL). Collectively, the top ten holdings represent about 24.51% of the total assets under management.

Performance and Risk

The JSML ETF aims to match the performance of the Janus Small Cap Growth Alpha Index before fees and expenses. This index selects small-sized capitalization stocks that are positioned for smart growth through a comprehensive evaluation based on growth, profitability, and capital efficiency metrics. Over the course of the current year, the ETF has presented an impressive 12.93% return and has surged approximately 33.87% over the last year (as of October 21, 2024). In the previous 52 weeks, the ETF traded within the range of $47.39 and $66.71. It has a beta of 1.25 and a standard deviation of 25.31% for the trailing three-year period, providing an effective diversification of company-specific risk with around 206 holdings.

Alternatives to Consider

Currently, the Janus Henderson Small Cap Growth Alpha ETF holds an ETF Rank of 3 (Hold), a rating based on expected asset class returns, expense ratios, and market momentum, among other factors. This makes it a suitable option for those looking for exposure in the Style Box – Small Cap Growth area of the market. Investors may want to explore other ETF options in this category, such as the iShares Russell 2000 Growth ETF (IWO) and the Vanguard Small-Cap Growth ETF (VBK), both of which track similar indices. The IWO has $12.26 billion in assets, while VBK boasts $18.51 billion, with expense ratios of 0.24% and 0.07%, respectively.

Conclusion

Investors, both retail and institutional, are increasingly gravitating toward passively managed ETFs. These products offer a range of advantages including low costs, transparency, flexibility, and tax efficiency, making them excellent vehicles for long-term investment strategies. To explore this ETF further and to identify other investment products that fit your investment objectives, consider visiting the ETF Center and keep informed on the latest developments within the ETF investing landscape.

Categories
Trading Tips

3 Must-Grab Momentum Stocks Set to Soar in Q4

3 Momentum Stocks to Snag for a Strong Q4

Wall Street’s momentum is heating up as we dive headfirst into the fourth quarter. The S&P 500 Index SPX and the Dow Jones Industrial Average $DOWI are breaking records, signaling a bullish momentum that traders shouldn’t ignore. This sentiment is amplified by a robust earnings season and the Federal Reserve’s soft landing approach. Jefferies analysts, led by U.S. small to mid-cap strategist Steven DeSanctis, are encouraging traders to ride the wave of momentum into year-end.

Momentum investing is all about capitalizing on trends—stocks that are rising tend to continue their ascent, while those in decline often drift lower. With that philosophy in mind, here’s a look at three hot momentum stocks that could propel your portfolio into a successful Q4:

Momentum Stock #1: Howmet Aerospace Inc. (HWM)

Pittsburgh-based Howmet Aerospace Inc. (HWM) is a key industrial supplier to the aviation and transport sectors. With a strong market cap of $43 billion, Howmet specializes in manufacturing precision components for jet engines and titanium structures while also providing forged aluminum wheels for heavy trucks.

Over the past 52 weeks, Howmet’s shares have skyrocketed nearly 138%, and they’re up 95% year-to-date (YTD), recently hitting a new high of $106.76. The big news? On September 25, Howmet declared a quarterly dividend of $0.08 per share, payable on November 25, with an annualized yield of 0.30%.

Howmet jumped over 13% after reporting better-than-expected fiscal Q2 earnings, with total revenue climbing 14% year-over-year to $1.9 billion. This growth was primarily driven by a phenomenal 27% uptick in the commercial aerospace market, and adjusted EPS soared 52% annually to $0.67.

With fiscal Q3 earnings on the horizon for November 6, optimism surrounds the stock. Consensus ratings give HWM a “Strong Buy” status, with 18 of 21 analysts advocating a “Strong Buy.”

Momentum Stock #2: Onto Innovation Inc. (ONTO)

Next up is Onto Innovation Inc. (ONTO), a Massachusetts-based leader in advanced semiconductor packaging. With a market cap of about $10.3 billion, Onto specializes in enhancing wafer quality, 3D metrology, and lithography solutions—leading its clients toward high-performance advances, particularly in artificial intelligence (AI) and high-bandwidth memory (HBM) projects.

ONT shares have appreciated 66.7% in the past year and are up 37% year-to-date. The stock surged over 8% post its impressive Q2 earnings report, which revealed a 27% year-over-year revenue increase to $242.3 million. This surge was driven by record revenues in specialty and advanced packaging, hitting $164 million.

Anticipating Q3 results on October 31, analysts forecast revenue in the range of $245 million to $255 million, and adjusted EPS between $1.25 and $1.35. Analysts predict Onto’s profits will leap 38.9% year-over-year to $5.18 per share in fiscal 2024, with continued robust growth projected into fiscal 2025. ONTO also holds a consensus rating of “Strong Buy,” with six out of seven analysts backing the stock fiercely.

Momentum Stock #3: US Foods Holding Corp. (USFD)

Last but not least, we have US Foods Holding Corp. (USFD), a cornerstone in the U.S. food service industry. Based in Rosemont, Illinois, this $15.3 billion company supplies a diverse array of fresh, frozen, and dry goods to various enterprises—from local diners to giant national chains.

USFD has experienced a robust 66.6% increase over the past year and has risen more than 37% in 2024, reaching a new all-time high of $63.13 on October 15. In its recent fiscal Q2 report on August 8, US Foods posted a revenue increase of 7.7% year-over-year to $9.7 billion, propelled by total case volume growth and food cost inflation, though adjusted EPS came in just shy of estimates.

Anticipation builds for November 7, when the company releases its Q3 earnings. Management estimates net sales between $37.5 billion and $38.5 billion, with adjusted EPS expected to range from $3.00 to $3.20. Analysts see US Foods’ profits surging 18.4% year-over-year to $2.90 in fiscal 2024 and expect another 20.3% increase to $3.49 in 2025. USFD enjoys a compelling “Strong Buy” consensus from analysts, with 11 out of 14 recommending a bullish stance.

As momentum trends persist, now is the time to pounce on these standout stocks. Keep your eyes peeled for earnings releases as Q4 unfolds and position yourself to take advantage of what promises to be a thrilling finish to the year.

Categories
Politics and Trading

Fed Rate Cuts in 2024: Navigating Economic Turbulence and Market Response

Fed’s Rate Cuts in 2024: A Misstep in Monetary Policy?

The Fed’s Dilemma: To Cut or Not to Cut

As 2024 approaches, the Federal Reserve is faced with an ongoing conundrum over its interest rate policy. This year has been characterized by a back-and-forth stance from the Fed, with dramatic shifts in its strategy regarding rate cuts. Initially, the Fed planned for a total of 150 basis points (BPS) in cuts, but as the economy displayed solid performance in the first half of the year, this projection rapidly evolved. With all signs pointing to an unexpected softening in crucial economic indicators, the perception in the bond market shifted dramatically, leading to fears of a recession.

Economic Indicators Signal a Shift

Throughout the summer, as manufacturing data indicated a substantial slowdown, the bond market began to price in expectations for 200 BPS of cuts within a single year. In response to these pressures, the Fed found itself in a perilous situation by October. The month prior to the U.S. presidential election, the Fed opted to cut rates by 50 BPS during the October Federal Open Market Committee (FOMC) meeting. Furthermore, they hinted at the possibility of additional cuts before the year’s end. This move was critical; cutting rates before an election could potentially ease economic anxieties, but it came with its own set of risks.

The Confounding Response from the Bond Market

Post the October meeting, instead of the anticipated rally, the bond market defied expectations and began to decline. Yields surged from the 10-year bond’s low of 3.5% to an alarming 4.09% in mere weeks. This unexpected volatility raises significant questions regarding the Fed’s credibility on the monetary front. While inflation figures moderated to an average of 2.9% to 3.2%, closer inspection reveals the ‘super core’ services CPI — excluding the housing index — has remained quite resilient around 4% or higher. Analysts argue that continuing to cut rates against a backdrop of stubborn inflation greatly undermines the Fed’s intended objectives.

A Balancing Act: The Implications of a “Goldilocks” Economy

The Fed’s actions, if left unchecked, could inadvertently support a “Goldilocks” economy: one that is neither too hot nor too cold, but also potentially unsustainable. However, the notion of a soft-landing scenario cannot coexist with the bond market’s anticipation of substantial interest rate cuts. Following the October policy direction, the bond market has adjusted its outlook, but equities continue to lean towards the belief that further cuts of 150 BPS are imminent.

Consumer Resilience Amid Market Shifts

Recent economic data offers mixed signals. A notable uptick in retail sales was reported, with the September figures showing a rise of 0.4%, exceeding expectations of 0.3%. Taking a closer look, retail sales excluding automobiles saw a surge of 0.5%, double the anticipated increase of 0.1%. These statistics paint a picture of a resilient U.S. consumer base, which remains robust even as inflation-adjusted numbers fall year over year.

Labor Market Stability as a Critical Metric

Other indicators, such as initial jobless claims, reveal a fluctuating but generally stable labor market. After an atypical spike due to unfortunate circumstances — such as storms and strikes — the latest data retreated to a more promising figure of 241,000, down from a revised high of 260,000. While the Fed tries to project itself as an apolitical entity, increasing pressure from various political figures could indicate its sensitivity to broader economic perceptions leading up to the election.

Reassessment of Future Rate Cuts

As the central bank continues to assert that “more work needs to be done,” this raises an undeniable question: if the Fed believes the economy requires continued vigilance, why pursue further cuts? If the dollar gains strength and the bond market removes its dovish stance, equity markets may soon awaken to the necessity of adapting to a higher permanent cost of capital. In a world where the days of negative interest rates are fading, it seems we are inching towards a financial landscape that may one day be recounted as a nostalgic period of cheap money.

Conclusion: The Fed’s Path Forward

The Federal Reserve finds itself at a critical juncture as 2024 unfolds. With the backdrop of persistent inflation and fluctuating consumer sentiment, it faces the daunting task of recalibrating policy while maintaining credibility in the eyes of both markets and the public. The challenge remains: can the Fed strike a balance that prevents economic stagnation while also curbing inflationary pressures without reverting to premature rate cuts? Only time will reveal its effectiveness in this high-stakes balancing act.

Categories
Financial News

America Thriving Against the Odds: Unveiling Progress Beyond the Headlines

America is Thriving Beyond the Headlines

In a time when political discontent and media narratives paint a bleak picture of the American landscape, it is crucial to remember that America, as a whole, is making remarkable strides. From advancements in technology to a booming entrepreneurial spirit, the nation is thriving beyond what many are led to believe. Here’s a look at the proof supporting the notion that America is doing better than often portrayed by politicians and the media.

A Shift in Public Sentiment

As we traverse through the challenges of the 21st century, it becomes starkly apparent that public satisfaction has veered downwards. According to a Gallup poll, in January 2000, a robust 69% of Americans expressed contentment with “the way things are going in the U.S.” Today, that number has plummeted to just 22%. This decline can be attributed to a myriad of significant events including the trauma following 9/11, extended military engagements, extreme financial downturns, and the catastrophic impacts of the COVID-19 pandemic – each contributing to a pervasive sense of dissatisfaction. It’s important to recognize that these sentiments have spanned both Republican and Democratic administrations, illustrating that political blame does not offer a comprehensive solution.

Employment: A Strong Foundation

The U.S. unemployment rate currently stands at 4.1%, accompanied by a staggering 8 million job openings. This discrepancy indicates that employers are facing difficulties in finding qualified workers to fill available positions. When considering the broader economic picture, the U.S. Gross Domestic Product (GDP) is growing at a pace of about 3%, significantly outpacing most other G-7 nations. The Financial Times notes that the U.S. is forecasted to grow at double the rate of any other G7 country this year, a testament to the resilience and dynamism of the world’s largest economy.

Inflation and Purchasing Power

The remnants of the pandemic-induced inflation appear to have receded, with the Social Security Administration’s cost-of-living adjustment for 2025 set to be only 2.5%. The U.S. Federal Reserve’s decision to reduce its key fed funds rate by 0.5% further signifies that inflationary pressures are lessening. In comparison to many developed countries, inflation rates in the U.S. have stabilized and wages are on the rise, exceeding inflation rates. This is crucial as it means Americans are regaining their purchasing power – a vital aspect of economic health.

A Surge in Entrepreneurship

One of the most promising trends emerging from this dynamic landscape is the uptick in entrepreneurship. The Small Business Administration (SBA) reported an all-time high of 5.5 million new business applications filed just last year. While failure rates for startups are high, the potential for transformative success remains, especially given the backing of a vibrant ecosystem of angel investors and venture capital. Innovative companies in growth sectors such as artificial intelligence, robotics, and clean energy are beginning to take root, driving the nation’s economic future.

Adapting to Future Needs

Beyond entrepreneurial endeavors, there is a notable shift in workforce education. As disillusionment with traditional college education increases, trade schools are witnessing a boom. Young Americans are seeking pragmatic alternatives that lead to well-paying jobs in high-demand fields, like plumbing and electrical work. In states like Texas, renewable energy is taking center stage, with almost 30% of electricity sourced from renewables, while still retaining a significant workforce in fossil fuels.

Technological Advancements and Innovations

The technological landscape in the U.S. is also burgeoning with advancements across numerous sectors. From breakthroughs in quantum computing to innovations in hydroponic farming, the pace of change is accelerating. Furthermore, the recent FAA approval of the first electric flying car highlights the potential for revolutionary advancements in transportation.

Conclusion: Embracing Unity for Progress

While it’s undeniable that America faces complex challenges, it is also clear that progress is being made on multiple fronts. The widening political divide and growing distrust in institutions pose serious threats, but progress at the grassroots level showcases the country’s resilience and innovation. In a perfect world, if lawmakers could transcend their partisan divides and collaborate for the common good, the potential for America to excel further is enormous. The road ahead may be fraught with difficulties, but the foundation of strong employment, a resilient economy, and innovative spirit suggests that **America is indeed thriving,** contrary to popular belief.

Categories
Technology

Top 3 Robotics Stocks to Invest in for the Automation Revolution

3 Robotics Stocks Powering the Automation Revolution

The robotics market is at the forefront of the automation revolution, driven by innovative breakthroughs in AI, machine learning, and improved safety features. This rapid advancement signifies a golden opportunity for investors interested in the growing landscape of robotics, which is reshaping various sectors, including air defense and medical technology. With the projection of substantial growth in this industry, here we explore three leading robotics stocks: RTX Corporation (RTX), Stryker Corporation (SYK), and Medtronic plc (MDT).

The Robotics Revolution and Its Impact

The integration of robotics and AI is transforming industries significantly. In the realm of air defense, robotics is enhancing soldier training, optimizing the use of unmanned aerial vehicles (UAVs), and improving logistic operations. This promises to increase combat effectiveness and improve cybersecurity measures as drone technology and autonomous systems evolve. As the industry progresses, analysts forecast a 14.7% compound annual growth rate (CAGR) for the global robotics market, expected to reach $283.19 billion by 2032.

Moreover, robotics is revolutionizing healthcare by introducing technologies that allow for precise surgeries, faster diagnoses, and improved rehabilitation processes. The global medical service robotics market alone reached $11.2 billion in 2024, with expectations to nearly double to $21 billion by 2028.

1. RTX Corporation (RTX)

RTX Corporation, a leader in the aerospace and defense sector, serves both commercial and military markets across the globe. The company operates through three divisions: Collins Aerospace, Pratt & Whitney, and Raytheon. In recent developments, RTX’s Raytheon secured full-rate production approval for its SM-3 Block IIA missile, a significant stride in its defense collaboration with Japan. Additionally, the company was awarded a $736 million contract from the U.S. Navy for AIM-9X Sidewinder missiles, reaffirming its stronghold in missile defense.

Financially, RTX exhibits robust performance with a trailing-12-month levered free cash flow (FCF) margin of 12.99%, outperforming the industry average of 6.55%. The second quarter of 2024 saw a 7.7% increase in sales to $19.72 billion. The company’s adjusted net income remained stable at $1.90 billion while its earnings per share (EPS) rose by 9.3% year-over-year to $1.41.

Over the past year, RTX shares have surged by 70.2%, closing at $125.75. Its POWR Ratings reflect strong fundamentals, holding a rating of B (Buy) across categories like Growth, Momentum, and Sentiment.

2. Stryker Corporation (SYK)

Stryker Corporation is a prominent medical technology company that operates through two main segments: MedSurg and Neurotechnology and Orthopaedics and Spine. Recently, Stryker completed the acquisition of Vertos Medical, enhancing its offerings for chronic lower back pain management. Furthermore, the company is expanding its healthcare IT capabilities with AI-assisted virtual care technologies.

Stryker’s trailing-12-month EBIT margin of 20.71% vastly exceeds the industry average of 2.66%. For Q2 2024, SYK’s net sales reached $5.42 billion, marking an 8.5% increase year-over-year. The adjusted EPS rose by 10.6% to $2.81, while net earnings increased by 11.2% to $1.09 billion.

The stock has appreciated by 33.8% over the past year, closing at $359.73. With a consistent track record of exceeding earnings expectations, Stryker holds strong potential in the medical device sector with a POWR rating of B.

3. Medtronic plc (MDT)

Medtronic, headquartered in Dublin, specializes in device-based medical therapies across multiple healthcare domains. The portfolio includes cardiovascular, neuroscience, surgical, and diabetes management solutions. Recently, Medtronic launched new technologies for its spine surgery ecosystem and secured FDA approval for its Simplera continuous glucose monitor.

Medtronic demonstrates impressive financial metrics with a trailing-12-month gross profit margin of 65.52%, significantly higher than the industry average of 57.66%. In its first-quarter results for the period ending July 2024, net sales grew by 2.8% to $7.92 billion, and net income surged by 31.7% to $1.04 billion.

Over the past year, MDT’s stock increased by 23.3%, closing at $89.79. The company enjoys a positive growth outlook and is rated B in terms of overall performance and growth potential.

Conclusion

As the automation revolution continues to gain momentum, investing in robotics stocks like RTX, Stryker, and Medtronic presents a promising opportunity for investors looking to capitalize on their growth potential. From enhancing military capabilities to revolutionizing healthcare practices, these companies are at the forefront of the robotics market, ensuring a bright future ahead.

Categories
Resource Stocks

Investing in a Nuclear Future: Why Uranium and Utility Stocks Are the Key to Big Tech’s Energy Needs

Uranium and Utilities Stocks: A Nuclear Future for Big Tech

As an investor passionate about nuclear energy, I’ve long recognized its monumental potential, especially with the recent surge in uranium and utility stocks. These sectors have drastically outperformed the S&P 500, with gains upward of 400%-500% since I first advocated for them in 2017. Today, with major tech stalwarts like Microsoft, Oracle, Apple, and Alphabet making significant commitments to nuclear energy, it seems prudent to explore the trends and implications fueling this nuclear renaissance.

The Big Tech Shift to Nuclear Energy

Microsoft’s recent agreement with Constellation Energy (CEG) to restart a nuclear reactor at the former Three Mile Island plant highlights the intensifying race for electricity among tech giants. This partnership is expected to provide much-needed energy to power massive data centers essential for advancing artificial intelligence (AI) technologies. Interestingly, Morgan Stanley analyses suggest that Microsoft is paying at least a 100% premium over the current market rates for electricity—amounting to approximately $100 per megawatt hour (MWh)—with total costs potentially exceeding $130 when transmission charges are included.

Why Nuclear Energy Demand is Rising

There are three main drivers of increased demand for nuclear energy in the coming years:

1. Booming Energy Demand

The appetite for electricity, primarily driven by massive data centers operating AI applications, is set to surge. The Boston Consulting Group (BCG) predicts that demand from data centers will grow by 15%-20% annually, reaching an estimated 16% of the United States’ total energy consumption by 2030. Moreover, the reshoring of industries such as chip manufacturing, electric vehicles, and renewable energy solutions is only expected to compound energy needs further.

2. Geopolitical Instability

Recent geopolitical events, notably the Russia-Ukraine conflict, have underscored the vulnerabilities inherent in energy sourcing. As nations grapple with energy security, the pivot towards nuclear capacity has gained renewed urgency. John Ciampaglia, CEO of Sprott Asset Management, emphasizes that this global realization will drive investment into nuclear energy as a stabilizing factor in volatile times.

3. The Drive for Decarbonization

The escalating responses to climate change, often through severe weather events, are fueling interest in sustainable energy solutions. Tim Gitzel, CEO of uranium producer Cameco (CCJ), notes that carbon-free nuclear energy is increasingly depicted as a vital component in tackling climate change. The pervasive governmental and public support for nuclear energy is helping to establish a consistent demand trend unlike anything seen in recent history.

Stock Opportunities in the Nuclear Sector

As the momentum for nuclear energy continues to build, several categories of stocks are poised to benefit greatly from this trend:

Nuclear-Powered Utilities

Morgan Stanley’s analysis suggests that the Microsoft-Constitution deal highlights the growing value of nuclear power for large data center operators. Analysts have upgraded price targets for major unregulated nuclear utilities such as Constellation, Vistra (VST), and Public Service Enterprise Group (PEG). For example, Constellation’s price target has been raised from $233 to $313, reflecting the anticipated change in market dynamics.

Infrastructure and Regulated Utilities

While some analysts remain cautious, believing market valuations are overly optimistic about growth, others point to bigger opportunities in regulated utilities. Companies such as NiSource (NI), WEC Energy Group (WEC), and Duke Energy (DUK) are strategically positioned to benefit from the increasing demand for energy linked to data centers and industrial reshoring initiatives. Regulated utilities have a stable framework to earn a consistent return on investment between 9%-10%, thus providing reliability for investors.

Uranium Miners and ETFs

Despite the growing demand for nuclear energy, challenges abound in uranium supply, with key production cuts occurring in Kazakhstan and other countries that historically produced a significant share of the world’s uranium supply. Consequently, prices for uranium are projected to rise as demand continues to outstrip supply. Investment options in this niche include the Sprott Physical Uranium Trust (SRUUF), as well as the Sprott Uranium Miners ETF (URNM) and Sprott Junior Uranium Miners ETF (URNJ), providing investors with diversified exposure to this burgeoning sector.

Conclusion

The shift towards nuclear energy, particularly driven by the needs of Big Tech, signals a transformative period in both energy generation and investment strategy. Leveling up investments in nuclear utilities, infrastructure, and uranium resources could yield significant returns as these industries evolve to meet the growing energy demands of an AI-driven future.

Categories
Small Stocks to Watch

3 Top Momentum Stocks to Buy for Q4 Success

3 Momentum Stocks to Snag for a Strong Q4

The Bullish Momentum on Wall Street

As the fourth quarter progresses, Wall Street’s momentum remains undeniably bullish, with the major market indices, including the S&P 500 and the Dow Jones Industrial Average, setting new record highs. With a robust start to the earnings season and the Federal Reserve navigating toward a soft landing, analysts at Jefferies recommend that investors capitalize on the momentum trade, which has historically tended to strengthen as the year comes to a close.

Momentum investing is centered on the belief that stocks that are currently rising will continue to do so, while those in decline will keep falling. Jefferies’ small-mid cap strategist, Steven DeSanctis, recently noted that “momentum has been red-hot and tends to keep its momentum heading into the last few months of a year.” Among the analyst’s top recommendations, here are three stocks worth considering as potential investments for continued upside.

Momentum Stock #1: Howmet Aerospace Inc. (HWM)

Pittsburgh-based Howmet Aerospace Inc. (HWM) is a significant player in the aerospace and transport sectors. Valued at approximately $43 billion, the company specializes in engineering precision components for jet engines and titanium structures, enhancing the lightness, speed, and fuel efficiency of aircraft while also supplying forged aluminum wheels for heavy trucks.

Howmet’s stock has skyrocketed nearly 138% over the past year and is up 95% year-to-date, recently reaching a high of $106.76. On September 25, Howmet announced a quarterly dividend of $0.08 per share, set for payment on November 25, marking an annualized dividend of $0.32 per share and offering a yield of 0.30%.

The company’s Q2 earnings, reported on July 30, surpassed expectations. Total revenue increased by 14% year-over-year to $1.9 billion, propelled by a 27% rise in the commercial aerospace market. Adjusted EPS also saw a notable 52% increase, reaching $0.67. As of Q2, Howmet possessed $752 million in cash and cash equivalents, an increase from $610 million at the end of 2023, with long-term debt reduced to $2.9 billion from $3.5 billion. Management has raised its 2024 revenue guidance to between $7.40 billion and $7.48 billion, with adjusted EPS estimated between $2.53 and $2.57. Howmet’s Q3 earnings are anticipated on November 6. The stock holds a consensus “Strong Buy” rating, with 18 out of 21 analysts supporting this bullish outlook.

Momentum Stock #2: Onto Innovation Inc. (ONTO)

Based in Massachusetts, Onto Innovation Inc. (ONTO) specializes in advanced semiconductor packaging. The company’s technology suite, which includes wafer quality control, 3D metrology, and lithography solutions, is essential in the production of everything from nanometer transistors to substantial die interconnects, significantly enhancing yield and performance in semiconductor design.

Onto has seen its market capitalization rise to approximately $10.3 billion, with its stock climbing 66.7% over the past year and appreciating 37% in 2024 alone. Following a strong Q2 earnings report on August 9, shares surged by over 8%, with revenue increasing by 27% year-over-year to $242.3 million. This growth was driven primarily by high-performance computing and AI-related high-bandwidth memory projects, with specialty and advanced packaging revenue hitting a record high of $164 million.

With expected Q3 earnings set for October 31, Onto’s management forecasts revenues between $245 million and $255 million, while adjusted EPS is projected between $1.25 and $1.35. Analysts predict a 38.9% year-over-year profit increase to $5.18 per share in fiscal 2024, escalating further by 23.8% to $6.41 per share in fiscal 2025. ONTO possesses a consensus “Strong Buy” rating, with six out of seven analysts recommending a strong buy.

Momentum Stock #3: US Foods Holding Corp. (USFD)

US Foods Holding Corp. (USFD) plays a critical role in the U.S. food service industry, supplying restaurants, hospitals, and hotels with a variety of food products. Based in Rosemont, Illinois, the company has achieved a market cap of $15.3 billion, with stock performance reflecting a 66.6% increase over the past year and more than 37% gain in 2024. The stock reached a new all-time high of $63.13 on October 15.

US Foods’ recent fiscal Q2 earnings report, released on August 8, revealed substantial revenue growth—up 7.7% year-over-year to $9.7 billion, driven by case volume growth and food cost inflation. Adjusted EPS saw a 17.2% jump to $0.93. Moreover, US Foods recorded its 13th consecutive quarter of market share gains in independent restaurant case volume, up 5.7%, and made strides in expanding its presence through the acquisition of IWC Food Service for $220 million.

Looking ahead, US Foods will report fiscal Q3 earnings on November 7, with management projecting net sales between $37.5 billion and $38.5 billion and adjusted EPS between $3.00 and $3.20. Analysts expect a profit surge of 18.4% to $2.90 per share in fiscal 2024, with a further uptick of 20.3% to $3.49 in fiscal 2025. USFD also maintains a “Strong Buy” consensus rating, with 11 out of 14 analysts offering a strong buy recommendation.

Conclusion

As the year-end approaches, the momentum in the stock market appears to remain strong, with highlighted opportunities in Howmet Aerospace, Onto Innovation, and US Foods Holding. Investing in these momentum stocks could provide a strategic play for investors looking to capitalize on projected growth in Q4 and beyond. As always, it is essential to conduct thorough research and consider your investment strategy before diving in.

Categories
Pharma Stocks

Discover Top 5 Biotech Stocks Set to Outperform the Market in 2023

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

In mid-October, biotech stocks marked a significant recovery as they regained their 50-day moving average, propelled by encouraging results from Wave Life Sciences (WVE) in RNA editing. While the resurgence offers a glimmer of hope, it still falls short of the buoyant levels experienced during 2020 when biotech firms were thrust into the spotlight due to their roles in developing COVID-19 solutions. As society adjusts to living with the pandemic, other pressing concerns such as economic instability and political uncertainties have sidetracked interest in biotech stocks.

Notably, the biotech industry group boasts a Relative Strength Rating of 83, positioning it within the top 17% of all industry groups based on 12-month performance metrics. This article highlights five biotech stocks that stand out in the current market landscape, driven by both technical and fundamental strengths:

1. Corcept Therapeutics (CORT)

Leading the charge within biotech is Corcept Therapeutics, recognized for its diverse pipeline aimed at treating various conditions such as Cushing syndrome, cancer, neurological diseases, and psychiatry. It has gained significant attention for its flagship product, Korlym, designed for Cushing syndrome patients suffering from type 2 diabetes. In the second quarter, Corcept reported adjusted earnings of 32 cents per share, achieving $163.8 million in sales. These figures represented a 14% increase in earnings, surpassing expectations by 9 cents per share, while sales grew over 39%, exceeding Wall Street forecasts.

Corcept’s stock has recently broken out of a cup base with a buy point at 39.75 on September 17. With a strong Composite Rating of 96 and a Relative Strength Rating of 97, it is classified as a Tech Leader. Investors are advised to consider taking profits when shares rise 20% to 25% above the entry point.

2. United Therapeutics (UTHR)

Another top contender is United Therapeutics, which specializes in chronic disease medications. Its primary product, Tyvaso, is a treatment for pulmonary arterial hypertension (PAH) that saw a sales increase of 25% to reach $398.2 million in the June quarter. However, this figure did not meet expectations of $403.3 million, leading analysts to scrutinize the company’s pipeline more closely. United Therapeutics now anticipates the results of a final-phase PAH study in 2026, delayed from previous projections for 2025.

The stock hit a record high intraday on September 3 but has since experienced a setback. With a remarkable Composite Rating of 98, it maintains a slightly lower Relative Strength Rating of 93. Shares have recently broken out of a flat base, with a new buy point set at 366.08.

3. Halozyme Therapeutics (HALO)

Halozyme Therapeutics shines as a leader in drug delivery systems. Its proprietary Enhanze technology facilitates subcutaneous drug administration, positively impacting numerous large-market medications, including Johnson & Johnson’s Darzalex Faspro and Roche’s Herceptin. Recently, Halozyme secured approval for a subcutaneous version of Roche’s multiple sclerosis medication, now marketed as Ocrevus Zunovo.

In the second quarter, Halozyme’s performance included adjusted earnings of 91 cents per share, with sales of $231.4 million, both surpassing analyst expectations. The biotech company maintains robust full-year guidance with projected adjusted earnings ranging from $3.65 to $4.05 per share. Despite lingering below its 50-day moving average as of October 18, Halozyme has strong ratings of 96 for Composite and 84 for Relative Strength, and it is also listed as a Tech Leader.

4. Harmony Biosciences (HRMY)

Focusing on a singularly innovative product, Harmony Biosciences has gained traction with its narcolepsy treatment, Wakix (pitolisant). The company perceives its drug portfolio as a “portfolio in a product opportunity,” exploring pitolisant’s efficacy against various conditions such as idiopathic hypersomnia and Prader-Willi syndrome.

In the second quarter, sales of Wakix reached $172.8 million, a 29% year-over-year increase, aligning closely with analyst expectations. While Harmony’s shares are currently trading below their 50-day line and struggling to reach a buy point of 35.40 from a consolidation, it boasts a Composite Rating of 98 and an RS Rating of 81, positioning it among the Tech Leaders.

5. ADMA Biologics (ADMA)

Last but not least, ADMA Biologics faced challenges after its independent auditor unexpectedly resigned on October 10, resulting in a 16% dip in stock value. Despite maintaining forward guidance for 2024 and 2025, ADMA, known for its human immune globulin products aimed at treating immunodeficiencies, has seen a decline in valuation.

Prior to this setback, ADMA’s stock had surged 31% on August 9 following an adjusted earnings report of 14 cents per share, substantially exceeding the expected 8 cents. Sales soared 78% to $107.2 million, surpassing projections. While currently trading below its 50-day moving average, ADMA remains above its 200-day moving average and boasts the highest possible Relative Strength and Composite ratings of 99.

Investors should keep a close eye on these five biotech stocks as they navigate the current market landscape, particularly given their resilience in performance metrics even amidst broader market uncertainties.

Categories
Technology

Sam Altman’s Nuclear Startup Soars 100% Amid Surge in Energy Demand from Tech Giants

This Sam Altman Startup Has Exploded 100% This Month as Nuclear Stocks Heat Up

The nuclear power startup backed by OpenAI head Sam Altman has seen its stock price surge over 100% in October, reflecting a booming interest in nuclear energy as major hyperscalers ramp up their investments in this sector to support their vast data centers and artificial intelligence (AI) initiatives. The surge in nuclear energy stocks, including Oklo—Altman’s startup—has been significantly influenced by major deals between technology giants and nuclear power providers.

Nuclear Power and Tech Giants: A New Renaissance

The renaissance of nuclear energy stocks has been particularly pronounced since late September, following an announcement from Microsoft (MSFT) regarding a two-decade contract with Constellation Energy (CEG) to supply nuclear power for its data centers. This influential move has been quickly echoed by other tech leaders; both Amazon (AMZN) and Alphabet (GOOGL) have recently entered into agreements to invest in the development of small modular reactor (SMR) technology, a field poised for innovation and expansion.

Interestingly, while SMRs do not currently exist in mainstream use, numerous companies are diligently working to bring this promising technology to development. In March, Amazon, recognizing the growing demand for sustainable energy, made a significant investment of $650 million in Talen Energy, acquiring a nuclear-powered data center campus in Pennsylvania. As data consumption from applications in AI surges, hyperscalers including Amazon, Microsoft, Alphabet, and Meta (META) are increasingly weighing the benefits of nuclear energy to alleviate rising energy demands from their data centers.

AI’s Energy Demand Driving Nuclear Stocks Up

In 2024, the synergy between nuclear power and the artificial intelligence sector is becoming ever clearer. As energy consumption continues to evolve, there are predictions that data center energy demand in the U.S. will escalate from approximately 4% of total energy demand now to 11%-12% by 2030, according to McKinsey & Co. This projection serves as a driving force for technology companies, who are now exploring investments and partnerships with nuclear providers to secure a stable energy supply for their rapidly growing data infrastructures.

Supporting this trend, Morgan Stanley analysts have noted that a “nuclear renaissance” is underway, despite the historical controversies surrounding nuclear power. They project a staggering $1.5 trillion investment in new nuclear capacity by 2050. Recent deals, including that between Constellation and Microsoft, are seen as pivotal in demonstrating the viability and potential profitability of nuclear power for hyperscale data operators.

Market Reactions and Stock Performances

The enthusiasm surrounding nuclear stocks is reflected in the recent market activity. Key players in the space, such as Vistra (VST) and Constellation Energy, have experienced significant stock performance fluctuations. For example, Vistra saw a reduction of 6.2% during Thursday’s market trading but had jumped 5.7% on Wednesday. Meanwhile, Constellation Energy faced similar volatility, dropping 3% on Thursday but gaining over 5% just a day prior. Since the Microsoft-Constellation deal announcement on September 20, these stocks have risen 46% and 34%, respectively.

In a further sign of confidence, JPMorgan initiated coverage on both Constellation Energy and Vistra Energy with an “overweight” rating, setting a $342 price target for Constellation and $178 for Vistra, indicating a potential upside of 22% and 31% from current trading levels.

Oklo and the Small Modular Reactor Market

Among the notable performers in the nuclear stock rally is Oklo, which recorded a staggering 104% increase in October alone and a 150% surge since the Microsoft agreement became public. However, after reaching a peak, it fell by 5% on Thursday. The notable investor interest has been illustrated through ARK Invest’s Cathie Wood, who has accumulated a position in Oklo worth over $2 million since July, and Peter Thiel’s significant stake in the startup.

Additional Players in the Nuclear Sector

Other companies in the SMR space, like Nano Nuclear Energy (NNE) and NuScale Power, experienced declines alongside Oklo; however, they previously witnessed notable increases. Uranium refiner Cameco (CCJ) also made headlines as it received recognition as one of the largest global suppliers of uranium, hitting a high of 7.8% earlier in the week. Meanwhile, Uranium Energy (UEC), engaged in uranium exploration in both the U.S. and Paraguay, saw a boost of 4.7% after receiving crucial regulatory approvals to enhance production capacity.

As investments in nuclear power and SMR technology continue to rise, it is clear that the nuclear industry is entering a transformative phase, driven by the confluence of technological innovation and the urgent need for sustainable energy solutions.